Related Experiment Video

Updated: Jun 8, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Therapeutic potential of antisense oligodeoxynucleotides in downregulating p53 oncogenic mutations in cancers

Zhigang Xie1, Wee Joo Chng, Kian Ghee Tay

  • 1Cancer Science Institute of Singapore, National University of Singapore, Singapore 117456, Singapore.

Biotechnology Letters
|October 1, 2010
PubMed
Abstract

Insights

Researchers designed p53 antisense oligonucleotides (ASOs) that precisely target mutant p53 genes. These ASOs effectively inhibited cancer cell growth and survival, demonstrating potential for targeted cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The p53 gene is frequently mutated in human cancers, driving tumor development.
  • Targeting specific p53 mutations offers a potential therapeutic strategy.

Purpose of the Study:

  • To design and validate a repository of p53 antisense oligonucleotides (ASOs) capable of discriminating between mutant and wild-type (WT) p53.
  • To assess the efficacy of these ASOs in inhibiting mutant p53 expression and cancer cell progression.

Main Methods:

  • Utilized Sfold software for predicting target accessibility of ASOs.
  • Designed a series of ASOs targeting specific p53 mutants (A161T, R175H, R249S).
  • Employed Western-blot analysis to evaluate ASO inhibition of p53 expression in human tumor cell lines.

Main Results:

  • ASOs demonstrated potent inhibition of mutant p53 expression in various cancer cell lines.
  • ASOs showed minimal impact on wild-type p53 expression.
  • Treatment with mutant-specific ASOs led to dose-dependent reduction in cancer cell growth, viability, colony formation, and invasion.

Conclusions:

  • A single nucleotide difference in ASOs can effectively distinguish between mutant and WT p53.
  • A p53 ASO repository shows promise as a tool for knocking down oncogenic mutant p53.
  • Further in vivo studies are warranted to validate the therapeutic potential of p53 ASO repositories.

More Related Videos

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...